Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Getinge Resumes Cardiovascular Shopping Spree With Datascope Purchase

This article was originally published in The Gray Sheet

Executive Summary

Getinge is continuing to solidify its position in the cardiovascular device market with its $865 million acquisition of intra-aortic balloon pump maker Datascope, announced Sept. 16

You may also be interested in...



Getinge’s Maquet Grows In Cardiology And Elsewhere With Atrium Buy

Swedish conglomerate Getinge Group is buying diversified device firm Atrium Medical for $680 million in a move that will expand its cardiovascular device business while adding new areas such as biosurgery and thoracic drainage products.

Getinge’s Maquet Grows In Cardiology And Elsewhere With Atrium Buy

Swedish conglomerate Getinge Group is buying diversified device firm Atrium Medical for $680 million in a move that will expand its cardiovascular device business while adding new areas such as biosurgery and thoracic drainage products.

Sorin/Datascope

Cardiac surgery device maker Sorin will acquire the Clearglide endoscopic vessel harvesting business of Datascope for undisclosed terms under an agreement announced Nov. 26. Getinge agreed to buy all of Datascope in September, but the firm said it was prepared to divest the Clearglide unit due to overlap with Getinge's own endoscopic vessel harvesting business (1"The Gray Sheet" Sept. 22, 2008, p. 15)

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026591

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel